RxDoctor Payments Data

Nainesh Patel, MD

Cardiovascular Disease · Pottstown, PANPI 1043290372

Payments from drug & device makers

$3,935in general payments, 2019–2025

Across 167 payments — averaging $23.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$926
  • Novartis$567
  • Pfizer$403
  • Amgen$278
  • Medtronic$212
  • Shockwave Medical, Inc$202
  • plus $1K from 17 others

What the payments were for

  • Travel & lodging$3088%
  • Food & beverage$3,62092%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,935 in reported general payments places this provider in the 65th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$299,810
Medicare patients
2,411
Services billed
4,779

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban732$764,321
XareltoRivaroxaban215$228,697
EntrestoSacubitril/Valsartan37$49,920
MultaqDronedarone Hcl11$23,002
Repatha SyringeEvolocumab18$18,063
Metoprolol Succinate782$14,203
Praluent PenAlirocumab16$13,096
Dofetilide38$10,252
BrilintaTicagrelor17$9,569
Atorvastatin Calcium617$6,343
Losartan Potassium414$4,626
Ezetimibe150$4,165
Rosuvastatin Calcium241$3,996
Ranolazine ErRanolazine33$3,229
Valsartan78$2,933

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$403$764,321732 claims
Johnson & JohnsonXarelto$38$228,697215 claims
NovartisEntresto$567$49,92037 claims
Sanofi-aventis U.S. LLCMultaq$64$23,00211 claims
AstraZenecaBrilinta$136$9,56917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Pottstown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →